AbbVie EBITDA 2010-2018 | ABBV

AbbVie annual and quarterly EBITDA history from 2010 to 2018. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • AbbVie EBITDA for the quarter ending September 30, 2018 was $3.594B, a 16.95% increase year-over-year.
  • AbbVie EBITDA for the twelve months ending September 30, 2018 was $12.345B, a 6.6% increase year-over-year.
  • AbbVie 2017 annual EBITDA was $11.093B, a 4.92% increase from 2016.
  • AbbVie 2016 annual EBITDA was $10.573B, a 26.27% increase from 2015.
  • AbbVie 2015 annual EBITDA was $8.373B, a 99.5% increase from 2014.
AbbVie Annual EBITDA
(Millions of US $)
2017 $11,093
2016 $10,573
2015 $8,373
2014 $4,197
2013 $6,561
2012 $6,967
2011 $4,892
2010 $5,901
2009 $5,629
AbbVie Quarterly EBITDA
(Millions of US $)
Q3 2018 $3,594
Q2 2018 $3,205
Q1 2018 $3,348
Q4 2017 $2,198
Q3 2017 $3,073
Q2 2017 $3,041
Q1 2017 $2,781
Q4 2016 $2,686
Q3 2016 $2,665
Q2 2016 $2,676
Q1 2016 $2,546
Q4 2015 $2,374
Q3 2015 $2,112
Q2 2015 $2,042
Q1 2015 $1,845
Q4 2014 $-222
Q3 2014 $1,152
Q2 2014 $1,717
Q1 2014 $1,550
Q4 2013 $1,735
Q3 2013 $1,605
Q2 2013 $1,689
Q1 2013 $1,532
Q4 2012 $2,130
Q3 2012 $1,823
Q2 2012 $1,717
Q1 2012 $1,297
Q4 2011 $-5,562
Q3 2011 $4,724
Q2 2011 $4,592
Q1 2011 $1,139
Q4 2010 $0
Q4 2009 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $132.702B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.162B 18.20
Pfizer (PFE) United States $259.069B 14.60
Novartis AG (NVS) Switzerland $204.655B 17.49
Merck (MRK) United States $201.163B 17.43
Eli Lilly (LLY) United States $119.057B 20.93
Sanofi (SNY) France $112.613B 13.94
Novo Nordisk (NVO) Denmark $107.980B 17.54
AstraZeneca (AZN) United Kingdom $105.090B 13.05
GlaxoSmithKline (GSK) United Kingdom $102.669B 13.80
Bristol-Myers Squibb (BMY) United States $85.837B 14.14